Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies within the biotechnology and pharmaceutical industries. The company excels in innovative automation and comprehensive biorepository services, facilitating faster drug discovery while ensuring adherence to stringent regulatory standards. With a forward-looking strategy that leverages advanced storage technologies and strategic partnerships, Azenta is uniquely positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to pioneering scientific research through sophisticated innovations underscores its potential appeal to institutional investors seeking exposure in the dynamic life sciences sector.
| Revenue (TTM) | $613.81M |
| Gross Profit (TTM) | $270.37M |
| EBITDA | $33.01M |
| Operating Margin | -2.27% |
| Return on Equity | -7.04% |
| Return on Assets | -0.73% |
| Revenue/Share (TTM) | $13.41 |
| Book Value | $34.51 |
| Price-to-Book | 0.91 |
| Price-to-Sales (TTM) | 2.24 |
| EV/Revenue | 1.784 |
| EV/EBITDA | 33.26 |
| Quarterly Earnings Growth (YoY) | 8778.00% |
| Quarterly Revenue Growth (YoY) | 12.00% |
| Shares Outstanding | $43.81M |
| Float | $38.38M |
| % Insiders | 1.05% |
| % Institutions | 117.29% |
Volatility is currently expanding
BURLINGTON, Mass., Sept. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA).
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., Aug. 24, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company.
AZTA went down for a long time, resulting in a multi-year low in May 2026, but the stock has rallied higher since then. While the stock has doubled in value, there is a chart that suggests to be wary of the rally because it could unwind itself in the near future. The current financial model from AZTA makes a case for being long, but that depends on whether AZTA can hit the targets laid out.
Azenta, Inc. (AZTA) Q3 2026 Earnings Call Transcript
Azenta NASDAQ: AZTA reported third-quarter fiscal 2026 revenue that exceeded its outlook, as growth in recurring-revenue businesses and improved Multiomics performance helped offset continued unevenness in capital equipment markets.
BURLINGTON, Mass., Aug. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.
BURLINGTON, Mass., July 22, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2026 earnings which ended on June 30, 2026, on Tuesday, August 4, 2026, after the market closes.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AZTA and any ticker you trade — then tracks every position and per-strategy win rate.
